Section 8 establishes Essential Documents - the documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced; demonstrate compliance with GCP and applicable regulatory requirements. Essential Documents categorized by trial phase (before clinical phase commences + during clinical conduct + after completion or termination) and party (sponsor + investigator + IRB/IEC). Trial Master File (TMF): sponsor-side + investigator site file; essential documents collection + organisation + index + accessibility + integrity; ICH E6 + TMF Reference Model (DIA 2017 + updates) + EMA TMF Guidance + FDA. Electronic TMF (eTMF): increasing adoption + R3 supports + integrity + audit trail + access control + electronic signature; system validation per Annex 1; integration with EDC + safety + financial systems; metadata + workflow + version control. Archive + Retention: minimum 15 years post-marketing authorisation or per local regulation (longest); subject identification confidentiality preserved during retention; medium suitable for retention (paper + electronic); periodic integrity check; destruction after retention with sponsor approval; transfer in case of company merger + acquisition + divestment. FDA 21 CFR Part 312.62 (sponsor) + Part 312.62 (investigator) + Part 11 + EU CTR + Annex 19 (Reference Standards). Coordinates with DIA TMF Reference Model + EMA TMF Guidance + Phlexglobal + Veeva Vault. ICH E6 + Essential Documents + TMF + eTMF + Archive applies.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.